Kwality Pharmaceuticals Limited has announced significant board decisions and arrangements for its upcoming 42nd Annual General Meeting (AGM), scheduled for September 9, 2025. The company's Board of Directors has approved several reappointments and new appointments, subject to shareholder approval at the AGM.

Director Reappointments

The Board has approved the reappointment of several key directors for five-year terms, from January 16, 2026, to January 15, 2031:

• Ramesh Arora as Managing Director
• Ajay Kumar Arora as Whole Time Director
• Anju Arora as Whole Time Director
• Geeta Arora as Whole Time Director
• Kartik Kapur as Independent Director for his second term

New Appointments and Regularizations

• Vinod Kumar Sharma: The Board has approved the regularization of Vinod Kumar Sharma as Additional Independent Director.
• M/s Rishi Mittal & Associates: Appointed as Secretarial Auditors for a five-year term, subject to shareholder approval.

AGM Details and Important Dates

Additional Board Approvals

The Board has also approved:

1. The Report of Board of Directors for the financial year ended March 31, 2025.
2. The Notice of the 42nd AGM.
3. The appointment of Mr. Rishi Mittal as Scrutinizer for conducting the e-voting process for the 42nd AGM.

Kwality Pharmaceuticals has emphasized that all director reappointments and the auditor appointment are subject to shareholder approval at the upcoming AGM. The company will provide electronic voting facilities to its members through NSDL's platform, allowing shareholders holding shares in physical or demat mode as of the cut-off date (September 1, 2025) to cast their votes on the proposed resolutions.

This comprehensive set of decisions underscores Kwality Pharmaceuticals' commitment to corporate governance and its preparation for the next phase of leadership continuity. Shareholders and investors will be keenly watching the outcomes of these proposals at the forthcoming AGM.

Kwality Pharmaceuticals Limited , a leading exporter of pharmaceutical formulations, has reported strong financial results for the first quarter of fiscal year 2026, demonstrating significant growth across key metrics.

Financial Highlights

• Consolidated revenue surged by 39.8% year-on-year to ₹111.80 crore, up from ₹80.00 crore in the same quarter last year.
• EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) grew by 39% to ₹24.60 crore, maintaining a stable margin of around 22%.
• Net profit increased by 43% to ₹11.90 crore, compared to ₹8.30 crore in Q1 FY25.

Operational Achievements

The company's strong performance was driven by increased sales of registered products across key international markets. During the quarter, Kwality Pharmaceuticals successfully completed a regulatory audit in Zimbabwe, reinforcing its position in the ZAZIBONA region and broader African market.

Expansion and Future Outlook

Kwality Pharmaceuticals continues to focus on expanding its global footprint and enhancing its product portfolio:

• The company received multiple new product registrations during the quarter.
• An EU-GMP audit for its general and beta-lactam manufacturing facilities is scheduled for October, marking a significant milestone in its European expansion efforts.
• Preparations are underway for a WHO-GMP inspection of the company's biologics facility later this year.
• Kwality has initiated line expansion to scale up production capacity for its first biological product, Erythropoietin (EPO).

Management Commentary

The management expressed confidence in achieving their revenue target of ₹500.00 crore for FY26. The company continues to focus on building a robust international regulatory footprint, driving margin-accretive growth, and investing in differentiated, high-barrier products for sustained value creation.

About Kwality Pharmaceuticals

Kwality Pharmaceuticals is a research-driven leader in the export of formulations, specializing in complex and niche injectables. The company operates five state-of-the-art manufacturing facilities with regulatory approvals from various regions, including PICs (ANVISA and SFDA), INVIMA, DIGEMED, and EUGMP. With a diverse portfolio exceeding 3,000 formulations across more than 25 therapeutic areas, Kwality Pharma exports its products to over 70 countries worldwide.

The company's strong Q1 FY26 performance and ongoing expansion efforts position it well for continued growth in the global pharmaceutical market.